Exelixis (EXEL) News Today $37.66 -0.06 (-0.15%) As of 10:32 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Summit Global Investments Has $382,000 Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL)Summit Global Investments decreased its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 55.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 11,483 shares of the biotechnology company'sMarch 25 at 4:29 AM | marketbeat.comNatixis Advisors LLC Has $2.03 Million Stock Position in Exelixis, Inc. (NASDAQ:EXEL)Natixis Advisors LLC raised its stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 109.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 60,850 shares of the biotechnology company's stock after acquiringMarch 25 at 3:36 AM | marketbeat.comBiotech Leader Exelixis Eyes Buy Point In Today's Stock Market RallyMarch 24 at 2:20 PM | msn.comBiotech Leader Exelixis Eyes Buy Point In Monday's Stock Market RallyMarch 24 at 12:01 PM | investors.comMagnetar Financial LLC Acquires Shares of 13,447 Exelixis, Inc. (NASDAQ:EXEL)Magnetar Financial LLC acquired a new stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 13,447 shares of the biotechnology company's stock, valued at approximaMarch 24 at 4:42 AM | marketbeat.comMarietta Investment Partners LLC Purchases Shares of 54,294 Exelixis, Inc. (NASDAQ:EXEL)Marietta Investment Partners LLC purchased a new stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 54,294 shares of the biotechnology company's stock, valued aMarch 23 at 7:02 AM | marketbeat.comHarvest Fund Management Co. Ltd Makes New Investment in Exelixis, Inc. (NASDAQ:EXEL)Harvest Fund Management Co. Ltd purchased a new position in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 13,202 shares of the biotechnology company's stoMarch 23 at 4:48 AM | marketbeat.comHighTower Advisors LLC Buys 10,391 Shares of Exelixis, Inc. (NASDAQ:EXEL)HighTower Advisors LLC lifted its stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 16.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 75,119 shares of the biotechnology company's stock after buying an additional 10,391 shares durMarch 23 at 3:20 AM | marketbeat.comProficio Capital Partners LLC Buys Shares of 21,212 Exelixis, Inc. (NASDAQ:EXEL)Proficio Capital Partners LLC bought a new stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 21,212 shares of the biotechnology company's stock, valued at approximately $7March 23 at 3:10 AM | marketbeat.comExelixis, Inc. (NASDAQ:EXEL) Given Consensus Rating of "Moderate Buy" by BrokeragesShares of Exelixis, Inc. (NASDAQ:EXEL - Get Free Report) have been given an average rating of "Moderate Buy" by the twenty ratings firms that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and elevMarch 22 at 4:11 AM | marketbeat.comExelixis, Inc. (NASDAQ:EXEL) Stock Holdings Trimmed by Connor Clark & Lunn Investment Management Ltd.Connor Clark & Lunn Investment Management Ltd. reduced its stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 65.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 26,225 shares of the biotechnology compMarch 22 at 3:44 AM | marketbeat.comExelixis, Inc.March 21, 2025 | cnn.comLingohr Asset Management GmbH Sells 22,986 Shares of Exelixis, Inc. (NASDAQ:EXEL)Lingohr Asset Management GmbH decreased its stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 71.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 9,007 shares of the biotechnology company's stock after selling 2March 21, 2025 | marketbeat.comIntech Investment Management LLC Has $8.92 Million Position in Exelixis, Inc. (NASDAQ:EXEL)Intech Investment Management LLC lifted its holdings in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 15.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 267,725 shares of the biotechnology compaMarch 20, 2025 | marketbeat.comAmundi Sells 14,170 Shares of Exelixis, Inc. (NASDAQ:EXEL)Amundi lessened its stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 37.3% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 23,805 shares of the biotechnology company's stock after selling 14,170 shares during the quartMarch 20, 2025 | marketbeat.comBank of America Securities Keeps Their Hold Rating on Exelixis (EXEL)March 19, 2025 | markets.businessinsider.comExelixis Growth Continues with Big Money BoostsMarch 19, 2025 | finance.yahoo.comExelixis, Inc. (NASDAQ:EXEL) Short Interest UpdateExelixis, Inc. (NASDAQ:EXEL - Get Free Report) was the target of a significant decline in short interest in the month of February. As of February 28th, there was short interest totalling 13,290,000 shares, a decline of 17.7% from the February 13th total of 16,150,000 shares. Based on an average trading volume of 2,480,000 shares, the days-to-cover ratio is presently 5.4 days. Currently, 4.9% of the shares of the company are short sold.March 19, 2025 | marketbeat.comExelixis, Inc. (EXEL): Among the Best Biotech Stocks to Buy According to BillionairesMarch 18, 2025 | msn.comSkandinaviska Enskilda Banken AB publ Buys Shares of 12,600 Exelixis, Inc. (NASDAQ:EXEL)Skandinaviska Enskilda Banken AB publ purchased a new position in Exelixis, Inc. (NASDAQ:EXEL - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 12,600 shares of the biotechnoloMarch 18, 2025 | marketbeat.comRaymond James Financial Inc. Purchases New Holdings in Exelixis, Inc. (NASDAQ:EXEL)Raymond James Financial Inc. purchased a new stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 511,879 shares of the biotechnology company's stock, valued at approximately $17,046,000. RMarch 18, 2025 | marketbeat.comVictory Capital Management Inc. Reduces Position in Exelixis, Inc. (NASDAQ:EXEL)Victory Capital Management Inc. lessened its stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 38.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 83,650 shares of the biotechnology company's stock after selling 52,528March 17, 2025 | marketbeat.comExelixis, Inc. (NASDAQ:EXEL) is Globeflex Capital L P's 6th Largest PositionGlobeflex Capital L P lifted its position in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 203.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 975,151 shares of the biotechnology company's stock after purchMarch 16, 2025 | marketbeat.comExelixis (NASDAQ:EXEL) Price Target Raised to $40.00March 16, 2025 | americanbankingnews.comExelixis (NASDAQ:EXEL) Price Target Raised to $40.00 at Royal Bank of CanadaRoyal Bank of Canada increased their price target on Exelixis from $38.00 to $40.00 and gave the company an "outperform" rating in a report on Thursday.March 14, 2025 | marketbeat.comExelixis at Leerink Global Healthcare Conference: Strategic Growth and InnovationMarch 14, 2025 | investing.com81,932 Shares in Exelixis, Inc. (NASDAQ:EXEL) Purchased by Wealthfront Advisers LLCWealthfront Advisers LLC purchased a new position in Exelixis, Inc. (NASDAQ:EXEL - Free Report) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 81,932 shares of the biotechnology company's stock, valued at approximatelyMarch 14, 2025 | marketbeat.comExelixis (EXEL) Up 13.4% Since Last Earnings Report: Can It Continue?March 13, 2025 | msn.comExelixis price target raised to $40 from $38 at RBC CapitalMarch 13, 2025 | markets.businessinsider.comExelixis: Pinning Hopes On Cracking One Of The Toughest NutsMarch 13, 2025 | seekingalpha.comJupiter Asset Management Ltd. Has $13.98 Million Stake in Exelixis, Inc. (NASDAQ:EXEL)Jupiter Asset Management Ltd. decreased its stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 81.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 419,951 shares of the biotechnology company's stock after sellingMarch 13, 2025 | marketbeat.comAlphaQuest LLC Has $503,000 Position in Exelixis, Inc. (NASDAQ:EXEL)AlphaQuest LLC lowered its holdings in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 49.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 15,115 shares of the biotechnology company's stock after seMarch 13, 2025 | marketbeat.comEXEL vs. ARGX: Which Stock Should Value Investors Buy Now?March 12, 2025 | msn.comExelixis (NASDAQ:EXEL) Shares Down 5.3% - Here's WhyExelixis (NASDAQ:EXEL) Shares Down 5.3% - What's Next?March 12, 2025 | marketbeat.comAshton Thomas Private Wealth LLC Takes $240,000 Position in Exelixis, Inc. (NASDAQ:EXEL)Ashton Thomas Private Wealth LLC purchased a new stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 7,199 shares of the biotechnology company's sMarch 12, 2025 | marketbeat.comExelixis (NASDAQ:EXEL) Sets New 1-Year High - Here's WhyExelixis (NASDAQ:EXEL) Reaches New 52-Week High - Should You Buy?March 11, 2025 | marketbeat.comRuffer LLP Buys New Stake in Exelixis, Inc. (NASDAQ:EXEL)Ruffer LLP purchased a new stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 110,757 shares of the biotechnology company's stock, valued at approximately $3,688,00March 10, 2025 | marketbeat.comBanco Santander S.A. Purchases New Holdings in Exelixis, Inc. (NASDAQ:EXEL)Banco Santander S.A. purchased a new stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 24,295 shares of the biotechnology company's sMarch 10, 2025 | marketbeat.comCapital Management Corp VA Has $11.12 Million Position in Exelixis, Inc. (NASDAQ:EXEL)Capital Management Corp VA lessened its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 8.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 334,045 shares of the biotechnology compaMarch 9, 2025 | marketbeat.comEdgestream Partners L.P. Boosts Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL)Edgestream Partners L.P. boosted its stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 50.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 110,293 shares of the biotechnology companMarch 9, 2025 | marketbeat.comJackson Creek Investment Advisors LLC Invests $301,000 in Exelixis, Inc. (NASDAQ:EXEL)Jackson Creek Investment Advisors LLC bought a new position in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 9,045 shares of the biotechnology company's stock, valued at approximately $301,000. SeveralMarch 9, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Has $108.30 Million Holdings in Exelixis, Inc. (NASDAQ:EXEL)Charles Schwab Investment Management Inc. decreased its position in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 0.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,252,353 shares of the biotechnology company's stockMarch 9, 2025 | marketbeat.comProficio Capital Partners LLC Makes New Investment in Exelixis, Inc. (NASDAQ:EXEL)Proficio Capital Partners LLC acquired a new stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 21,212 shares of the biotechnology company's stock, valued at approximaMarch 9, 2025 | marketbeat.comInceptionr LLC Acquires New Position in Exelixis, Inc. (NASDAQ:EXEL)Inceptionr LLC acquired a new stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 24,437 shares of the biotechnology company's stock, valued at approximately $814,March 8, 2025 | marketbeat.comZacks Research Has Negative Outlook of Exelixis Q1 EarningsExelixis, Inc. (NASDAQ:EXEL - Free Report) - Investment analysts at Zacks Research dropped their Q1 2025 earnings estimates for shares of Exelixis in a research note issued to investors on Monday, March 3rd. Zacks Research analyst E. Bagri now anticipates that the biotechnology company will postMarch 7, 2025 | marketbeat.comExelixis, Inc. (NASDAQ:EXEL) Stock Position Lifted by Candriam S.C.A.Candriam S.C.A. lifted its stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 12.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 614,671 shares of the biotechnology coMarch 7, 2025 | marketbeat.comOppenheimer & Co. Inc. Takes $561,000 Position in Exelixis, Inc. (NASDAQ:EXEL)Oppenheimer & Co. Inc. acquired a new stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 16,836 shares of the biotechnology company's stock, valued at approximately $561,000. Other hedge funds alMarch 7, 2025 | marketbeat.comInsider Selling: Exelixis, Inc. (NASDAQ:EXEL) EVP Sells 10,000 Shares of StockExelixis, Inc. (NASDAQ:EXEL - Get Free Report) EVP Patrick J. Haley sold 10,000 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $38.80, for a total value of $388,000.00. Following the sale, the executive vice president now owns 341,028 shares of the company's stock, valued at approximately $13,231,886.40. This trade represents a 2.85 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.March 6, 2025 | marketbeat.comExelixis, Inc. (NASDAQ:EXEL) Short Interest Up 23.4% in FebruaryExelixis, Inc. (NASDAQ:EXEL - Get Free Report) was the target of a significant increase in short interest in February. As of February 15th, there was short interest totalling 16,150,000 shares, an increase of 23.4% from the January 31st total of 13,090,000 shares. Currently, 5.9% of the company's stock are short sold. Based on an average daily volume of 2,320,000 shares, the short-interest ratio is presently 7.0 days.March 6, 2025 | marketbeat.comZacks Research Has Bullish Outlook for Exelixis Q2 EarningsExelixis, Inc. (NASDAQ:EXEL - Free Report) - Investment analysts at Zacks Research upped their Q2 2025 EPS estimates for Exelixis in a research report issued to clients and investors on Monday, March 3rd. Zacks Research analyst E. Bagri now anticipates that the biotechnology company will earn $0.March 6, 2025 | marketbeat.com Remove Ads Get Exelixis News Delivered to You Automatically Sign up to receive the latest news and ratings for EXEL and its competitors with MarketBeat's FREE daily newsletter. Email Address EXEL Media Mentions By Week EXEL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EXEL News Sentiment▼1.230.63▲Average Medical News Sentiment EXEL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EXEL Articles This Week▼1912▲EXEL Articles Average Week Remove Ads Get Exelixis News Delivered to You Automatically Sign up to receive the latest news and ratings for EXEL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Alnylam Pharmaceuticals News Biogen News United Therapeutics News BioMarin Pharmaceutical News Incyte News Neurocrine Biosciences News Exact Sciences News Repligen News Halozyme Therapeutics News Madrigal Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EXEL) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exelixis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exelixis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
